ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer
{{output}}
Introduction: Aromatase inhibitors (AI) plus CDK4/6 inhibitors are the current first-line standard-of-care for hormone receptor (HR)-positive/HER2-negative advanced breast cancer (ABC). However, mutations in ESR1 (ESR1m), the gen... ...
